Incidence of constipation associated with long-acting opioid therapy: A comparative study

被引:50
|
作者
Staats, PS
Markwitz, J
Schein, J
机构
[1] Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Div Pain Med, Baltimore, MD 21205 USA
[2] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA
[3] Hlth Data Analyt, Princeton, NJ USA
[4] Janssen Pharmaceut Prod LP, Titusville, NJ USA
关键词
constipation; fentanyl transdermal system; morphine; controlled-release; opioid analgesics; oxycodone controlled-release;
D O I
10.1097/01.SMJ.0000109215.54052.D8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Opioid therapy plays a key role in the management of chronic pain. Constipation is one of the more frequently occurring adverse effects associated with opioid therapy. Methods: A retrospective cohort design study was conducted determine the incidence of constipation in chronic pain patients who received three different long-acting opioids (transdermal fentanyl, oxycodone HCl controlled-release [CR], or morphine CR) for malignant or nonmalignant chronic pain. The data source was claims data (January 1996 through March 2001) from a 20% random sample of the California Medicaid (Medi-Cal) database. Claims data were from adult patients with chronic pain (malignant or nonmalignant) who had no prior diagnosis of constipation and no prior usage of long-acting opioids for at least 3 months before the observation period. Patients were followed for at least 3 months after the initiation of opioid therapy. ICD-9 code for diagnosis of constipation was the main outcome variable. Crude rates of constipation, annual incidence density, relative risk, and adjusted odds ratios were compared. Results: A total of 1,836 patients (601 receiving transdermal fentanyl, 721 receiving oxycodone CR, and 514 receiving morphine CR) were included in the analysis. Crude (unadjusted) rates of constipation were 3.7% for transdermal fentanyl, 6.1% for oxycodone CR, and 5.1% for morphine CR (P > 0.05). Transdermal fentanyl had a lower annual incidence density and risk of constipation than oxycodone CR and morphine CR (P > 0.05). After adjusting for confounding variables, including race and supplemental opioid use, the adjusted risk of constipation was 78% greater in the oxycodone CR group (P = 0.0337) and 44% greater in the morphine CR group (P = 0.2242) than in the transdermal fentanyl group. Conclusion: In this population, patients receiving transdermal fentanyl had a lower risk of developing constipation compared with those receiving oxycodone CR or morphine CR.
引用
收藏
页码:129 / 134
页数:6
相关论文
共 50 条
  • [21] The Impact of Tamper-Deterrent Long-Acting Oxycodone on Long-Acting Opioid Prescribing Rates Across Canada
    Gomes, Tara
    Mastorakos, Andrea
    Paterson, Michael
    Sketris, Ingrid
    Caetano, Patricia
    Henry, David
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 : 211 - 212
  • [22] Long-acting Opioid Use and the Risk of Serious Infections: A Retrospective Cohort Study
    Wiese, Andrew D.
    Griffin, Marie R.
    Schaffner, William
    Stein, C. Michael
    Greevy, Robert A.
    Mitchel, Edward F., Jr.
    Grijalva, Carlos G.
    CLINICAL INFECTIOUS DISEASES, 2019, 68 (11) : 1862 - 1869
  • [23] STUDY ON LONG-ACTING AKINESIA
    TANAKA, H
    MINAMI, M
    KAWABE, H
    FOLIA OPHTHALMOLOGICA JAPONICA, 1978, 29 (06): : 888 - 894
  • [24] Opioid addiction: long-acting formulations for a long-term disorder
    Kunoe, Nikolaj
    Lee, Joshua D.
    LANCET, 2019, 393 (10173): : 723 - 724
  • [25] COMPARATIVE EVALUATION OF SUBLINGUAL LONG-ACTING NITRATES
    KLAUS, AP
    ZARET, BL
    PITT, BL
    ROSS, RS
    CIRCULATION, 1973, 48 (03) : 519 - 525
  • [26] COMPARATIVE-STUDY OF 2 LONG-ACTING TRANQUILIZERS FOR ORAL PREMEDICATION
    DODSON, ME
    EASTLEY, RJ
    BRITISH JOURNAL OF ANAESTHESIA, 1978, 50 (10) : 1059 - 1064
  • [27] RADIOENDOCRINE THERAPY OF BRAIN-TUMORS WITH THE LONG-ACTING OPIOID ANTAGONIST NALTREXONE IN ASSOCIATION WITH RADIOTHERAPY
    LISSONI, P
    MEREGALLI, S
    FOSSATI, V
    BARNI, S
    TANCINI, G
    BARIGOZZI, P
    FRIGERIO, F
    TUMORI, 1993, 79 (03) : 198 - 201
  • [28] Methadone as the Initial Long-Acting Opioid in Children with Advanced Cancer
    Madden, Kevin
    Mills, Sarah
    Dibaj, Seyedeh
    Williams, Janet L.
    Liu, Diane
    Bruera, Eduardo
    JOURNAL OF PALLIATIVE MEDICINE, 2018, 21 (09) : 1317 - 1321
  • [29] Predictors of availability of long-acting medication for opioid use disorder
    Shover, Chelsea L.
    Humphreys, Keith
    DRUG AND ALCOHOL DEPENDENCE, 2019, 204
  • [30] Long-Acting Injectable Naltrexone for the Management of Patients with Opioid Dependence
    Kjome, Kimberly L.
    Moeller, F. Gerard
    SUBSTANCE ABUSE-RESEARCH AND TREATMENT, 2011, 5 : 1 - 9